ES2142729A1 - Proteinic product, process for its preparation, compositions containing it and use in medicaments - Google Patents

Proteinic product, process for its preparation, compositions containing it and use in medicaments

Info

Publication number
ES2142729A1
ES2142729A1 ES009701666A ES9701666A ES2142729A1 ES 2142729 A1 ES2142729 A1 ES 2142729A1 ES 009701666 A ES009701666 A ES 009701666A ES 9701666 A ES9701666 A ES 9701666A ES 2142729 A1 ES2142729 A1 ES 2142729A1
Authority
ES
Spain
Prior art keywords
strains
preparation
group comprised
medicaments
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES009701666A
Other languages
Spanish (es)
Other versions
ES2142729B1 (en
Inventor
Mejias Fernando Chacon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to ES009701666A priority Critical patent/ES2142729B1/en
Priority to PCT/ES1998/000219 priority patent/WO1999006441A1/en
Priority to AU84424/98A priority patent/AU8442498A/en
Publication of ES2142729A1 publication Critical patent/ES2142729A1/en
Application granted granted Critical
Publication of ES2142729B1 publication Critical patent/ES2142729B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention discloses a proteinic product extracted from non-pathogene bacillus and comprising proteins, peptides and other molecules obtained from the cellular lysis over at least one or the two sporulated and thermal resistant bacillus strains, in natural or modified form, and selected among a first group comprised of strains of B. Licheniformis, B. Circulans 2, B. Pumilus, B. Macerans, B. Amilolicuofaciens a second group comprised of strains of B. Cereus 1, B. Cereus 2, B. Lentus 1, B. Lentus 2 a third group comprised of strains of B. Subtilis a fourth group comprised of strains of B. Mesentericus. The invention also relates to a process for the preparation of the proteinic product, compositions which contain it and its use in the preparation of medicaments for the treatment of diseases related to syndromes of immunodeficiency, self-immunity, neoplasic processes, degenerative diseases, inflammatory intestinal diseases and infectious diseases.
ES009701666A 1997-07-29 1997-07-29 PROTEIN PRODUCT, PROCEDURE FOR ITS PREPARATION, COMPOSITIONS THAT CONTAIN IT, AND ITS USE IN MEDICINES. Expired - Fee Related ES2142729B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES009701666A ES2142729B1 (en) 1997-07-29 1997-07-29 PROTEIN PRODUCT, PROCEDURE FOR ITS PREPARATION, COMPOSITIONS THAT CONTAIN IT, AND ITS USE IN MEDICINES.
PCT/ES1998/000219 WO1999006441A1 (en) 1997-07-29 1998-07-28 Proteinic product, process for its preparation, compositions containing it and use in medicaments
AU84424/98A AU8442498A (en) 1997-07-29 1998-07-28 Proteinic product, process for its preparation, compositions containing it and use in medicaments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009701666A ES2142729B1 (en) 1997-07-29 1997-07-29 PROTEIN PRODUCT, PROCEDURE FOR ITS PREPARATION, COMPOSITIONS THAT CONTAIN IT, AND ITS USE IN MEDICINES.

Publications (2)

Publication Number Publication Date
ES2142729A1 true ES2142729A1 (en) 2000-04-16
ES2142729B1 ES2142729B1 (en) 2000-12-16

Family

ID=8300210

Family Applications (1)

Application Number Title Priority Date Filing Date
ES009701666A Expired - Fee Related ES2142729B1 (en) 1997-07-29 1997-07-29 PROTEIN PRODUCT, PROCEDURE FOR ITS PREPARATION, COMPOSITIONS THAT CONTAIN IT, AND ITS USE IN MEDICINES.

Country Status (3)

Country Link
AU (1) AU8442498A (en)
ES (1) ES2142729B1 (en)
WO (1) WO1999006441A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES400418A1 (en) * 1972-03-03 1975-01-01 Chacon Mejias Procedure for the isolation and obtaining of proteins constituting a preventive and curative vaccine of malignant tumor processes. (Machine-translation by Google Translate, not legally binding)
ES410892A1 (en) * 1973-01-23 1975-12-01 Chacon Mejias Process for the production of an injectable preparation
JPS60190720A (en) * 1984-03-09 1985-09-28 Agency Of Ind Science & Technol Antitumor agent having acyl group
WO1994022459A1 (en) * 1993-04-07 1994-10-13 Eisai Co., Ltd. Immunopotentiative and infection-protective agent, containing two or more bacillus, egg white and garlic
WO1995004539A1 (en) * 1993-08-11 1995-02-16 Ahc Inc. Immunopotentiator and method of immunopotentiating animal with the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES400418A1 (en) * 1972-03-03 1975-01-01 Chacon Mejias Procedure for the isolation and obtaining of proteins constituting a preventive and curative vaccine of malignant tumor processes. (Machine-translation by Google Translate, not legally binding)
ES410892A1 (en) * 1973-01-23 1975-12-01 Chacon Mejias Process for the production of an injectable preparation
JPS60190720A (en) * 1984-03-09 1985-09-28 Agency Of Ind Science & Technol Antitumor agent having acyl group
WO1994022459A1 (en) * 1993-04-07 1994-10-13 Eisai Co., Ltd. Immunopotentiative and infection-protective agent, containing two or more bacillus, egg white and garlic
WO1995004539A1 (en) * 1993-08-11 1995-02-16 Ahc Inc. Immunopotentiator and method of immunopotentiating animal with the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BASE DE DATOS PAJ en EPOQUE. Japanese Patent Inf. Organisation (TOKIO, JP) & JP 60190720 A (KOGYO GIJUTSUIN) 28.09.1985 *

Also Published As

Publication number Publication date
AU8442498A (en) 1999-02-22
ES2142729B1 (en) 2000-12-16
WO1999006441A1 (en) 1999-02-11

Similar Documents

Publication Publication Date Title
HU9603251D0 (en) Lactobacillus strains of human origin, their compositions and uses thereof
ES2190653T3 (en) Reaction products of hyaluronic acid and amino NATURAL and their use in cosmetic and pharmaceutical compositions.
TR200200768T2 (en) New quinuclide derivatives and drug compositions containing it
DE60023870D1 (en) PROCESS FOR THE PREPARATION OF 3-ARYLOXY-3-ARYLPROPYLAMINE AND THEIR INTERMEDIATE PRODUCTS
MX336118B (en) Hybrid and tandem expression of neisserial proteins.
TR199802789T2 (en) Exendin analogues, methods for their production and pharmaceutical preparations containing them.
CA2291274A1 (en) Uses of oil bodies
DE69820450D1 (en) CHIMEAR VECTORS CONTAINING THE PACKAGING REGION OF A PHAGE GENENOM AND PART OF THE GENOME OF AN EUKARYONTIC VIRUS
NO990454D0 (en) Aerosol material
ATE210988T1 (en) CYTOTOXIC AMINO SUGAR AND RELATED SUGAR DERIVATIVES OF INDOLOPYRROLOCARBAZOLES
NO963133L (en) 12,13-isotaxol analogs, antineoplastic applications and pharmaceutical preparations containing them
DK1025237T3 (en) Human checkpoint kinase, hCDS1, preparations and methods
PT851926E (en) RANGE INTERFERENCE VARIABLES (RHU-IFN-RANGE) HUMAN RECOMBINANT WITH ENHANCED THERMAL STABILITY
ATE211391T1 (en) USE OF HMG PROTEINS FOR THE PRODUCTION OF MEDICINAL PRODUCTS WITH CYTOTOXIC ACTION
IL117209A (en) 1-aryl-2-acylamino-ethane compounds and pharmaceutical compositions containing them
BR9704067A (en) Improved riboflavin production
ATE314474T1 (en) CLONING OF THE GENE FOR THE T GONDII PROTEIN GP 28.5 PEPTIDE FRAGMENTS FROM THIS PROTEIN AND THEIR USES.
DE59610251D1 (en) CONJUGATE, INCLUDING AN ACTIVE SUBSTANCE, A POLYPEPTIDE AND A POLYETHER
IL141325A0 (en) Tan-1057 derivatives
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
DE69524971D1 (en) NEW FAMILY OF PROTEAS INHIBITORS AND OTHER BIOLOGICALLY ACTIVE SUBSTANCES
ES2142729A1 (en) Proteinic product, process for its preparation, compositions containing it and use in medicaments
MX9303257A (en) IMPROVEMENTS IN BACILLUS ALKALINE PROTEASES, IMPROVEMENTS IN WASHING COMPOSITIONS, AND IMPROVEMENTS IN A PROCEDURE FOR THE PREPARATION OF SUCH PROTEASES.
SE9400524L (en) energy Preparations
EP1449510A4 (en) Hair care products

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20000416

Kind code of ref document: A1

Effective date: 20000416

PC2A Transfer of patent
PC2A Transfer of patent

Effective date: 20130327

FD2A Announcement of lapse in spain

Effective date: 20171106